Search by Drug Name or NDC
NDC 49702-0248-13 Vocabria 30 mg/1 Details
Vocabria 30 mg/1
Vocabria is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is CABOTEGRAVIR SODIUM.
MedlinePlus Drug Summary
Cabotegravir is used along with rilpivirine (Edurant) as a short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older weighing at least 77 pounds (35 kg). Cabotegravir is used as a short-term prevention of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older wighing at least 77 pounds (35 kg). It is used to see if the body can tolerate cabotegravir before receiving the cabotegravir injection and in certain cases of missed doses of cabotegravir injection. Cabotegravir is in a class of medications called HIV integrase inhibitors. It works by decreasing the amount of HIV in the blood. Although cabotegravir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0248-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Cabotegravir
Product Information
| NDC | 49702-0248 |
|---|---|
| Product ID | 49702-248_9713d608-de29-46dd-a6c1-77b26d8be928 |
| Associated GPIs | 12103010200320 |
| GCN Sequence Number | 081868 |
| GCN Sequence Number Description | cabotegravir sodium TABLET 30 MG ORAL |
| HIC3 | W5U |
| HIC3 Description | ANTIVIRALS,HIV-1 INTEGRASE STRAND TRANSFER INHIBTR |
| GCN | 49106 |
| HICL Sequence Number | 046411 |
| HICL Sequence Number Description | CABOTEGRAVIR SODIUM |
| Brand/Generic | Brand |
| Proprietary Name | Vocabria |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | cabotegravir sodium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | CABOTEGRAVIR SODIUM |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA212887 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0248-13 (49702024813)
| NDC Package Code | 49702-248-13 |
|---|---|
| Billing NDC | 49702024813 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (49702-248-13) |
| Marketing Start Date | 2021-01-21 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |